CSPC Pharmaceutical Group Limited (CHJTF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CSPC Pharmaceutical Group Limited (CHJTF) trades at $0.98 with AI Score 50/100 (Grade B). CSPC Pharmaceutical Group Limited is a leading Chinese pharmaceutical company focused on the research, development, and manufacturing of a diverse range of pharmaceutical products. Market cap: $11.18B, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for CHJTF: CHJTF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CHJTF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
CHJTF: the 1 perspectives are evenly split.
How is this calculated? →CSPC Pharmaceutical Group Limited (CHJTF) Healthcare & Pipeline Overview
CSPC Pharmaceutical Group Limited stands out in the healthcare sector as a prominent pharmaceutical manufacturer, offering a broad portfolio of innovative products targeting critical health conditions, while maintaining a robust market presence in China and expanding internationally.
What Is the Investment Thesis for CHJTF?
CSPC Pharmaceutical Group Limited demonstrates strong growth potential driven by its diverse product portfolio and expanding international presence. The company has a market capitalization of $11.18B and a P/E ratio of 18.2, indicating investor confidence in its future earnings growth. With a profit margin of 14.9% and a gross margin of 66.7%, CSPC showcases operational efficiency and profitability. Key growth catalysts include the increasing demand for innovative healthcare solutions in China and beyond, as well as potential expansions into new markets. Additionally, CSPC's focus on research and development positions it well to capitalize on emerging healthcare trends. However, the company must navigate regulatory challenges and competitive pressures within the pharmaceutical industry, which could impact its growth trajectory.
Based on FMP financials and quantitative analysis
CHJTF Key Highlights
- Market capitalization of $11.18B reflects strong investor confidence.
- P/E ratio of 18.2 indicates favorable valuation compared to industry peers.
- Profit margin of 14.9% showcases effective cost management and operational efficiency.
- Gross margin of 66.7% exceeds industry averages, highlighting product profitability.
- Dividend yield of 2.63% provides a return to shareholders amid growth.
Who Are CHJTF's Competitors?
CHJTF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALBBY Alibaba Health Information Technology Limited | $8.00 | +0.00% | $6.45B | 46 |
| BDUUY Bangkok Dusit Medical Services Public Company Limited | $25.24 | +7.84% | $10.03B | 42 |
| BIOVF Swedish Orphan Biovitrum AB (publ) | $47.35 | -1.35% | $16.38B | 56 |
| ERFSF Eurofins Scientific SE | $78.98 | -1.53% | $13.67B | 43 |
| GIFLF Grifols, S.A. | $10.45 | +0.00% | $7.11B | 52 |
| ORINY Orion Oyj | $38.86 | +0.00% | $21.87B | 64 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 64 |
| ORINF Orion Oyj | $82.75 | +0.00% | $11.66B | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CHJTF's Key Strengths?
- Diverse product portfolio catering to various health conditions.
- Strong market presence in China and expanding internationally.
- High gross margin indicating effective cost management.
- Commitment to innovation through significant R&D investments.
What Are CHJTF's Weaknesses?
- Dependence on the Chinese market for a large portion of revenue.
- Potential regulatory challenges in international markets.
- Exposure to patent expiration risks affecting product sales.
- Limited brand recognition outside of Asia.
What Could Drive CHJTF Stock Higher?
- Expansion into new international markets to drive revenue growth.
- Continuous investment in R&D to develop innovative therapies.
- Strengthening partnerships with healthcare providers for product distribution.
- Launch of new products targeting chronic disease management.
- Focus on enhancing operational efficiencies to improve profit margins.
What Are the Key Risks for CHJTF?
- Regulatory challenges in international markets may hinder growth.
- Intense competition from established pharmaceutical companies.
- Patent expirations could impact revenue from key products.
- Economic fluctuations affecting healthcare spending and pricing.
What Are the Growth Opportunities for CHJTF?
- Expansion into international markets: CSPC is poised to capitalize on its existing product portfolio by entering new international markets. The global pharmaceutical market is expected to grow at a CAGR of 6.3% from 2021 to 2028, presenting significant opportunities for CSPC to increase its market share and revenue streams.
- Investment in R&D for innovative therapies: CSPC's commitment to research and development is a key driver for future growth. By focusing on the development of novel therapeutics, particularly in oncology and neurology, the company aims to address unmet medical needs and enhance its competitive positioning in the market.
- Increasing demand for chronic disease management: With rising incidences of chronic diseases such as diabetes and hypertension, CSPC's product offerings in these therapeutic areas are well-positioned to meet growing healthcare demands. The global diabetes market alone is projected to reach $100 billion by 2025, providing CSPC with ample growth potential.
- Strategic partnerships and collaborations: CSPC can enhance its growth trajectory through strategic partnerships with other pharmaceutical companies and research institutions. Collaborations can facilitate access to new technologies, expand product offerings, and accelerate time-to-market for innovative therapies.
- Focus on functional foods and healthcare services: The growing trend towards preventive healthcare and wellness presents an opportunity for CSPC to expand its functional food and healthcare services segments. The global functional food market is expected to reach $275 billion by 2025, allowing CSPC to diversify its revenue streams.
What Opportunities Does CHJTF Have?
- Expansion into emerging markets with growing healthcare needs.
- Development of innovative therapies in high-demand therapeutic areas.
- Increasing demand for functional foods and preventive healthcare solutions.
- Strategic partnerships to enhance product offerings and market reach.
What Threats Does CHJTF Face?
- Intense competition from domestic and international pharmaceutical companies.
- Regulatory changes impacting drug approval processes.
- Market fluctuations affecting pricing and profitability.
- Risks associated with supply chain disruptions and sourcing materials.
What Are CHJTF's Competitive Advantages?
- Strong brand recognition within the Chinese pharmaceutical market.
- Extensive product portfolio addressing a wide range of health conditions.
- Established relationships with healthcare providers and distributors.
- Commitment to research and development fostering innovation.
- Operational efficiencies leading to favorable profit margins.
What Does CHJTF Do?
CSPC Pharmaceutical Group Limited, founded in 1992 and headquartered in Shijiazhuang, China, is an investment holding company that specializes in the research, development, manufacture, and sale of pharmaceutical products. Originally known as China Pharmaceutical Group Limited, the company rebranded to its current name in March 2013 to reflect its growth and international ambitions. CSPC operates through three main segments: Finished Drugs, Bulk Products, and Functional Food and Others. Its extensive product portfolio includes treatments for acute ischemic stroke, mild to moderate memory impairment, Parkinson's disease, various cancers, and more. The company has developed notable products such as NBP soft capsules, Oulaining capsules, and Duomeisu, which address significant health challenges. CSPC's commitment to innovation and quality has positioned it as a key player in the pharmaceutical industry, not only in China but also across other Asian regions, the Americas, and Europe. With a workforce of approximately 21,400 employees, CSPC is dedicated to enhancing healthcare outcomes through its diverse range of pharmaceutical offerings and healthcare services.
What Products and Services Does CHJTF Offer?
- Research and develop a wide range of pharmaceutical products.
- Manufacture finished drugs and bulk pharmaceutical products.
- Offer functional food products and healthcare services.
- Provide treatments for various health conditions, including cancer and neurological disorders.
- Engage in international sales and distribution of pharmaceutical products.
- Focus on innovation and quality in drug development and manufacturing.
How Does CHJTF Make Money?
- Generate revenue through the sale of pharmaceutical products across various therapeutic areas.
- Leverage research and development to create innovative therapies that address unmet medical needs.
- Utilize a diversified product portfolio to mitigate risks associated with market fluctuations.
- Expand market presence through strategic partnerships and international distribution channels.
- Offer healthcare services and functional food products to diversify revenue streams.
What Industry Does CHJTF Operate In?
The pharmaceutical industry is experiencing significant growth, driven by increasing healthcare demands and advancements in drug development. CSPC Pharmaceutical Group Limited operates within this dynamic landscape, where the global pharmaceutical market is projected to reach $1.5 trillion by 2023. The company faces competition from both domestic and international players, including peers such as ALBBY, BDUUY, BIOVF, ERFSF, and GIFLF. CSPC's strategic focus on innovation and its established presence in China provide a competitive edge as the industry evolves to meet changing healthcare needs.
Who Are CHJTF's Key Customers?
- Hospitals and healthcare providers seeking pharmaceutical solutions.
- Patients requiring medications for chronic and acute health conditions.
- Distributors and wholesalers in the pharmaceutical supply chain.
- International markets looking for high-quality pharmaceutical products.
- Healthcare institutions requiring functional food and healthcare services.
ROE 11%Key Financial Metrics
Return on equity for CSPC Pharmaceutical Group Limited stands at 11.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 8.2%, showing how much profit it generates from its asset base. CHJTF trades at a trailing price-to-earnings ratio of 18.23, below the Healthcare sector average of ~23x. Its free cash flow yield is 5.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.19 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.5%, the inverse of the P/E and a quick read on earnings relative to price.
CSPC Pharmaceutical Group Limited (CHJTF) Valuation Context
Valued at $11.18B, CHJTF is classified as a large-cap stock. Relative to its peer group, CHJTF's quantitative score of 50/100 is roughly in line with the peer average of 48/100.
Company Profile
CSPC Pharmaceutical Group Limited operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Shijiazhuang, CN. The company is led by CEO Lei Cai. CHJTF has traded publicly since 2010.
F-Score 6/9Financial Health
CSPC Pharmaceutical Group Limited's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 7.24 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project CSPC Pharmaceutical Group Limited revenue of about $36.10B for fiscal 2026, with EPS near $0.75. The estimate reflects 21 contributing analysts.
CHJTF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's growth trajectory, indicating that executives believe in the future potential of CSPC.
- Positive community sentiment has emerged around the company's innovative drug pipeline, with discussions highlighting breakthrough therapies.
- Market perception has shifted favorably as CSPC continues to expand its presence in international markets, attracting attention from global investors.
- Recent collaborations with research institutions have bolstered the company's reputation, enhancing its credibility within the pharmaceutical sector.
Bear Case
- Concerns have been raised about regulatory challenges that could impact the approval timelines of new drugs, creating uncertainty among investors.
- Community discussions reflect skepticism regarding the sustainability of recent revenue growth, with some questioning the long-term viability of key products.
- Market sentiment has been tempered by broader economic factors affecting the pharmaceutical industry, leading to cautious outlooks from analysts.
- Insider selling activity has also been noted, raising red flags about potential internal concerns that could affect future performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
CHJTF Latest News
No recent news available for CHJTF.
CHJTF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CHJTF.
Price Targets
Wall Street price target analysis for CHJTF.
CHJTF MoonshotScore
What does this score mean?
The MoonshotScore rates CHJTF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Lei Cai
CEO
Lei Cai has extensive experience in the pharmaceutical industry, having held various leadership positions since joining CSPC Pharmaceutical Group Limited. With a strong educational background in pharmaceutical sciences, he has been instrumental in driving the company's strategic vision and operational excellence.
Track Record: Under Lei Cai's leadership, CSPC has achieved significant growth in revenue and market share, while expanding its product portfolio and international presence. His focus on innovation and quality has positioned the company as a leader in the pharmaceutical sector.
CHJTF OTC Market Information
The OTC Other tier includes companies that trade on the over-the-counter market but do not meet the requirements for higher tiers like OTCQX or OTCQB. This tier typically has less stringent reporting requirements, which may affect transparency and investor confidence.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure compared to companies listed on major exchanges.
- Lower liquidity may result in higher volatility and trading difficulties.
- Potential for less regulatory oversight affecting investor confidence.
- Risks associated with foreign exchange fluctuations impacting earnings.
- Verify the company's financial statements and disclosures.
- Assess the competitive landscape and market position.
- Review recent news and developments impacting the company.
- Evaluate the management team's track record and experience.
- Consider the company's growth strategy and market opportunities.
- Established presence in the pharmaceutical industry since 1992.
- Strong product portfolio with a focus on innovation and quality.
- Positive financial metrics indicating operational efficiency.
- Recognition and partnerships with healthcare providers and institutions.
What Investors Ask About CSPC Pharmaceutical Group Limited (CHJTF) — Healthcare
What does CSPC Pharmaceutical Group Limited do?
CSPC Pharmaceutical Group Limited is engaged in the research, development, manufacture, and sale of a diverse range of pharmaceutical products. The company focuses on addressing various health conditions through innovative therapies and operates in multiple segments, including Finished Drugs, Bulk Products, and Functional Food.
What do analysts say about CHJTF stock?
Analysts generally view CHJTF stock favorably, noting its strong market position and growth potential. Key valuation metrics such as a P/E ratio of 18.2 and a profit margin of 14.9% indicate a solid financial foundation. Analysts also highlight the company's commitment to R&D as a driver for future growth.
What are the main risks for CHJTF?
CSPC Pharmaceutical Group Limited faces several risks, including regulatory challenges that could impact its ability to enter international markets. Additionally, the company is exposed to intense competition from both domestic and international pharmaceutical firms, which may affect market share and pricing strategies. Patent expirations on key products also pose a risk to revenue generation.
What are the key factors to evaluate for CHJTF?
CSPC Pharmaceutical Group Limited (CHJTF) holds an AI score of 50/100 (moderate). P/E: 18.2x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does CHJTF data refresh on this page?
CHJTF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CHJTF's recent stock price performance?
CSPC Pharmaceutical Group Limited (CHJTF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio catering to various health conditions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CHJTF overvalued or undervalued right now?
CSPC Pharmaceutical Group Limited (CHJTF) trades at 18.2x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CHJTF?
Before investing in CSPC Pharmaceutical Group Limited (CHJTF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on the latest available information as of March 2026.